AFRESA(R) Phase 3 Pulmonary Function Safety Data In Patients With Diabetes Presented At ADA
AFRESA(R) Phase 3 Pulmonary Function Safety Data In Patients With Diabetes Presented At ADA
AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions.